大剂量氨溴索治疗顽固性肺不张的临床研究

目的探讨大剂量盐酸氨溴索治疗顽固性肺不张的临床效果和安全性。方法选取顽固性肺不张患者112例作为研究对象。根据入院顺序将患者随机分组，奇数者为观察组，偶数者为对照组，每组各56例，对照组主要接受对症治疗、物理治疗等常规疗法和常规剂量盐酸氨溴索。观察组在常规疗法的基础上加用大剂量盐酸氨溴索。对比分析两组间临床疗效和安全性。结果观察组显效率和总有效率分别为71．43％（40／56）和100．00％（56／56），均高于对照组的51．79％（29／56）和83．93％（47／56），差异均有统计学意义（χ2=4．57、9．79，均P〈0．05）。两组不良反应发生率差异无统计学意义（χ2=0．15，P〉0．05），且均未出现其他严重不良反应。结论大剂量盐酸氨溴索治疗顽固性肺不张的临床效果较既往常规治疗更优，安全性好，值得在临床上进一步推广。

The clinical research of refractory atelectasis treaed with high dosage ambroxol

Objective To explore the clinical effect of refractory atelectasis treated with high dose ambroxol. Methods 112 patients with refractory atelectasis were selected as research subjects. All the patients were divided into two groups with each group 56 patients according to admission order. The control group received symptom treat- ment,physics treatment and routine dosage ambroxol, while the observation group received high dose ambroxol. The clinical effect and safe between two groups were compared. Results The excellence rate and total effective rate of the observation group were 71.43% （40/56） and 100.00% （ 56/56 ）, respectively, which were higher than 51.79% （29/56） and 83.93 % （47/56） of the control group （ χ2 = 4.57,9.79, all P 〈 0.05 ）. There were no statistical differ- ence on the total adverse effect incidence rates between the two groups （χ2 = 0.15, R 〉 0.05 ）. No other sever adverse effects happened in both groups. Conclusion Compared with routine dosage ambroxol, the clinical effect of refractory atelectasis treated with high dose ambroxol was betterl The treatment was also safe. It was worth generalizing on the treatment of refractory atelectasis.